Allena Pharmaceuticals Inc. (ALNA)

10.63 -0.07 (-0.654%)

IEX Real-Time Price

August 17, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 10.7

Price Open 10.67

Volume: 19,414

Avg Volume: 81,344

Market Cap: 220.6M

P/E Ratio -2.23

52 Wk Range 6.13-17.56



ALNA Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
17.11M
218,276
2.56
1.28%

2018-07-13
17.06M
267,930
1.62
1.57%

2018-06-29
17.06M
311,887
2.06
1.83%

2018-06-15
17.06M
164,629
1.36
0.97%




ALNA Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-08
Q1 2018
N/A
-0.45 (4)
-0.38
0.07

2018-03-29
Q4 2017
N/A
-0.27 (2)
0.00
0.00

2018-03-27
Q4 2017
N/A
-0.27 (2)
-0.48
-0.21

2018-03-22
Q4 2017
N/A
-0.27 (2)
0.00
0.00

News

Allena Pharma's mid-stage basket study of ALLN-177 in hyperoxaluria underway (2018-07-23 09:20 SeekingAlpha)

The first subjects have been treated in an open-label Phase 2 basket study (Study 206) evaluating Allena Pharmaceuticals' (NASDAQ: ALNA ) lead candidate ALLN-177 in adults and adolescents with primary hyperoxaluria or enteric hyperoxaluria with advanced kidney disease and elevated plasma…

 


Statistics

Shares Outstanding: 20.75M

Top 15 Institution Percent: 94.00

Price To Sales: N/A

Price To Book: 3.28

Revenue: N/A

Gross Profit: N/A

Cash: 33.87M

Debt: 9.69M

Return On Assets: -47.09

Return On Equity: -59.43

Profit Margin: N/A

Price History

Beta: -4.14

50-day Moving Avg: 11.89

200-day Moving Avg: 11.57

YTD Change: -3.19

5-day Change: -2.03

1-month Change: -5.76

3-month Change: -33.56

6-month Change: 49.93

1-year Change: 6.51

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Allena Pharmaceuticals Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.allenapharma.com

Allena Pharmaceuticals Inc is a clinical biopharmaceutical company. It focuses on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders.